Biogen Idec (BIIB) Enrolls First Patient in Phase III Trial for ALS Treatment
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Join SI Premium – FREE
Biogen Idec (Nasdaq: BIIB) and Knopp Biosciences have enrolled the first patient in EMPOWER, a multi-national Phase III study evaluating the efficacy, safety and pharmacokinetics of dexpramipexole in patients with amyotrophic lateral sclerosis (ALS).
From the release:
"EMPOWER is a Phase III, randomized, double-blind, placebo-controlled, parallel-group, multi-center study that will assess the safety and efficacy of dexpramipexole in people with familial or sporadic ALS. Approximately 804 patients will be randomized in a one-to-one ratio to receive either dexpramipexole 150 mg twice daily or placebo and will be followed for a period of at least 12 months."
From the release:
"EMPOWER is a Phase III, randomized, double-blind, placebo-controlled, parallel-group, multi-center study that will assess the safety and efficacy of dexpramipexole in people with familial or sporadic ALS. Approximately 804 patients will be randomized in a one-to-one ratio to receive either dexpramipexole 150 mg twice daily or placebo and will be followed for a period of at least 12 months."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress
- Sonos launches OS 27 with AI control and two new products
- Vishay launches two common mode chokes for automotive and industrial use
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
